---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-024022"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T13:18:38.356050+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Relmada reports FY 2023 net loss of $98.8M; advancing Phase 3 MDD trials with data expected H2 2024

## Summary
- Q4 2023 net loss $25.2M ($0.84/share) vs $37.9M ($1.28) in Q4 2022; full-year net loss $98.8M ($3.28/share).
- Cash, equivalents and short-term investments at Dec 31, 2023: $96.3M, down from $148.3M a year earlier.
- R&D expense fell to $54.8M in FY 2023 from $113.3M in FY 2022, reflecting completion of prior Phase 3 trials.
- REL-1017 Phase 3 Reliance II enrollment on track; top-line data expected H2 2024; Relight enrollment targeted by year-end 2024.
- REL-P11 psilocybin Phase 1 in obese patients expected H1 2024; Phase 2a proof-of-concept data seen H1 2025.

## SEC filing metadata
- accession: 0001213900-24-024022
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390024024022/0001213900-24-024022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390024024022/ea0202135-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-024022
- JSON: https://secwatch.observer/filing/0001213900-24-024022.json
- Plain text: https://secwatch.observer/filing/0001213900-24-024022.txt

## Key facts
- Earnings Releases
  RELMADA THERAPEUTICS, INC. reported the fourth quarter and full year ended December 31, 2023 results: net income $98.8 million, EPS $3.28 per basic and diluted share.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Net income: $98.8 million
  - EPS: $3.28 per basic and diluted share
  - Result: preliminary results
  source text: Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the fourth quarter and full year ended December 31, 2023. (These results are preliminary and unaudited.)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1553643/000121390024024022/0001213900-24-024022-index.htm
- Earnings Releases
  RELMADA THERAPEUTICS, INC. reported the fourth quarter and full year ended December 31, 2023 results: net income $98.8 million, EPS $3.28 per basic and diluted share.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Net income: $98.8 million
  - EPS: $3.28 per basic and diluted share
  - Result: preliminary results
  source text: Net loss for the year ended December 31, 2023 and 2022 was $98.8 million and $157.0 million, respectively. The Company had a net loss of $3.28 and $5.30 per basic and diluted share for the year ended December 31, 2023 and 2022, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1553643/000121390024024022/0001213900-24-024022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.